Normunity appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer

Boston, Mass., and West Haven, Conn. – January 19, 2023 – Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced the appointment of Olga Granaturova, MBA, as Chief Operating Officer and Chief Business Officer. Ms. Granaturova brings over 25 years in the global biopharma industry with multi-disciplinary experience in corporate strategy, business development, R&D organization, portfolio management, and regulatory and commercialization strategies in biotechnology and pharmaceutical companies across many sizes and all stages of growth.

“We are delighted to welcome Olga to the Normunity Leadership Team. Her hands-on experience in business creation, financing and business development will play a vital role as we continue to grow,” said Rachel Humphrey, MD, founding Chief Executive Officer of Normunity. “Olga’s entrepreneurial spirit and scientific background are an ideal fit for our team, as we realize the tremendous opportunities enabled by our novel mechanisms in immuno-oncology and build a world-class biotech company.”

“I couldn’t imagine a more exciting time and opportunity to join Normunity, as the company is building momentum with its new approach to immune normalization in the fight against cancer,” said Ms. Granaturova. “I look forward to driving the next phases of development to help Normunity achieve its aspirations as a drug innovator in the immuno-oncology space with the potential to create numerous life-changing medicines for cancer patients.”

Olga Granaturova’s diverse experience spans the entire value chain from R&D to commercial launch, and she brings deep expertise in business functions including fundraising, licensing, partnering and M&A transactions. She joins Normunity after serving as co-founder and Chief Operating Officer of Parthenon Therapeutics, a biotech company creating a novel class of anti-cancer therapies. Based on her business leadership role at Parthenon, as well as serving as VP of business development at Evotec and founder and managing partner of the life sciences consulting firm, LENUS Group, she has hands-on experience in company creation for biotech start-ups as a founder, angel investor, and a startup mentor. Earlier in her career, Olga had tenures at top tier pharmaceutical companies, including as a leader in global regulatory development at Merck and as a drug discovery scientist at Pfizer. Over the course of her career, Olga has led teams to deliver 20 different clinical candidates, 3 drug launches, and several multi-year, multi-million dollar deals. In addition, Olga is co-founder and president of Brighter Ventures, a nonprofit organization advancing women-led entrepreneurship, and she serves on the board of Parthenon Therapeutics and Coucou Nous Voilou, a pediatric oncology nonprofit organization. She received a BS in Pharmaceutical Sciences from SUNY at Buffalo and a TRIUM Global MBA from the NYU Stern School of Business, HEC Paris and the London School of Economics, and was recently named to Inc.’s Female Founders 100 List, honoring women whose innovations and ideas are making the world into a better place.

About Normunity

Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn. For more information, please visit and follow us on LinkedIn.

Media Contact
Kathryn Morris, The Yates Network LLC


Back to Top